Sign Up Today and Learn More About Genome & Co. Stock
Invest in or calculate the value of your shares in Genome & Co. or other pre-IPO companies through EquityZen's platform.
Genome & Co. Stock (GECO)
Genome & Co (G&C) is a microbiome based research and development company focused on researching microbes and probiotics.
About Genome & Co. Stock
Founded
2015
Industries
Software, Artificial Intelligence, Data and Analytics
Genome & Co. Press Mentions
Stay in the know about the latest news on Genome & Co.
Genome & Co. stresses CNTN4-APP as next immuno-oncology target
bioworld • Oct 29, 2024
Genome Editing Market Size Will Achieve USD 25.58 Billion by 2032 growing at 15.3% CAGR - Published by Emergen
einnews • Jun 25, 2024
Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug ...
businesswire • Jun 25, 2024
Genome & Co. shares jump 30% on $426M cancer deal with Debiopharm
bioworld • Jun 05, 2024
Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials
kedglobal • Sep 21, 2023
Genome & Co. Management
Leadership team at Genome & Co.
Chief Technology Officer & Co-Chief Executive Officer
Hansoo Park
Co-Founder & Chief Executive Officer
Jisoo Pae
Join now and verify your accreditation status to gain access to:
- Genome & Co. current valuation
- Genome & Co. stock price
- Available deals in Genome & Co. and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Genome & Co. stock?
Accredited investors can buy pre-IPO stock in companies like Genome & Co. through EquityZen funds. These investments are made available by existing Genome & Co. shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Genome & Co. stock?
Shareholders can sell their Genome & Co. stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
